Simvastatin Increases Fibulin-2 Expression in Human Coronary Artery Smooth Muscle Cells via RhoA/Rho-Kinase Signaling Pathway Inhibition

Noemí Serra, Roser Rosales, Lluís Masana, Joan-Carles Vallvé

Facultat de Medicina, Unitat de Recerca en Lípids i Arteriosclerosi, Universitat Rovira i Virgili, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Institut Investigació Sanitària Pere Virgili (IISPV), Reus, Catalonia, Spain

* jc.vallve@urv.cat

Abstract

The composition and structure of the extracellular matrix (ECM) in the vascular wall and in the atherosclerotic plaque are important factors that determine plaque stability. Statins can stabilize atherosclerotic plaques by modulating ECM protein expression. Fibulins are important components of the ECM. We evaluated the in vitro effect of simvastatin on the expression of fibulin-1, -2, -4 and -5 in human coronary artery smooth muscle cells (SMCs) and the mechanisms involved. Cells were incubated with simvastatin (0.05–1 μM), mevalonate (100 and 200 μM), geranylgeranyl pyrophosphate (GGPP) (15 μM), farnesyl pyrophosphate (FPP) (15 μM), the Rho kinase (ROCK) inhibitor Y-27632 (15 and 20 μM), the Rac-1 inhibitor (another member of Rho family) NSC23766 (100 μM), arachidonic acid (a RhoA/ROCK activator, 25–100 μM) and other fatty acids that are not activators of RhoA/ROCK (25–100 μM). Gene expression was analyzed by quantitative real-time PCR, and fibulin protein levels were analyzed by western blotting and ELISA. Simvastatin induced a significant increase in mRNA and protein levels of fibulin-2 at 24 hours of incubation (p<0.05), but it did not affect fibulin-1, -4, and -5 expression. Mevalonate and GGPP were able to reverse simvastatin’s effect, while FPP did not. In addition, Y-27632, but not NSC23766, significantly increased fibulin-2 expression. Furthermore, activation of the RhoA/ROCK pathway with arachidonic acid decreased fibulin-2 mRNA. Simvastatin increased mRNA levels and protein expression of the ECM protein fibulin-2 through a RhoA and Rho-Kinase-mediated pathway. This increase could affect the composition and structure of the ECM.

Introduction

Atherosclerosis, the primary underlying cause of cardiovascular diseases, is a systemic disease of the arterial wall that leads to plaque development[1, 2]. During the progression of atherosclerosis, the structure, abundance, and composition of the arterial wall extracellular matrix...
(ECM) are deeply affected[3]. Moreover, the progression of plaque can lead to a so-called vulnerable-type plaque, characterized by a thin fibrous cap and intraplaque neovascularization and hemorrhage[4, 5] among other factors. The breakdown of ECM components (collagen, elastin, and others) by extracellular proteases in atherosclerotic plaques promotes fibrous cap thinning and destabilization[6, 7], which has been associated with major adverse clinical outcomes[8], such as myocardial infarction and stroke[4, 9, 10]. Intraplaque neovascularization is characterized by new immature and thin-walled micro-vessels derived from the adventitial vasa vasorum. The consequence of this reduced wall structure is a fragile network of new vessels that can easily rupture, causing intraplaque hemorrhage[11]. Furthermore, an increased density of these immature micro-vessels has been identified at the shoulders of atherosclerotic lesions where rupture is more frequently described[12–14].

Fibulins are a family of seven proteins that are important components of the ECM[15, 16], basement membranes[17] and elastic matrix fibers[18]. Exhibiting an extensive array of protein–protein interactions, fibulins act as intermolecular bridges between ECM components, connecting various supramolecular structures. Fibulins participate in the correct assembly of elastin and microfibrils to form elastic fibers. For instance, fibulin-1 and -2 bind to tropoelastin and proteoglycans, and fibulin-5 binds to tropoelastin and elastin fibers[19, 20]. Moreover, fibulin-2 binding to fibronectin and collagen in the basement membrane has been described[21]. Therefore, fibulins have an important structural function in the arterial wall and in different types of connective tissues. The dysregulation of certain fibulins occurs in a range of human disorders[22–27]. Moreover fibulin-2 has been shown to colocalize with versican and hyaluronan in in murine vascular atherosclerotic lesions[28].

Statins comprise a class of hypocholesterolemic agents used in people with or at risk for cardiovascular disease. They lower cholesterol by inhibiting HMG-CoA reductase, but in addition, statins have a wide range of pleiotropic effects[29–31], including the stabilization of atherosclerotic plaques[32, 33]. In this regard, it has been shown that statin therapy in animal models modifies the biology of the atherosclerotic plaque and increases its stability[34]. Moreover, collagen and fibrotic content of plaques significantly increases in patients receiving statin treatment, conferring resistance to rupture and plaque stabilization[35–39]. Some of these non-lipid related actions may be explained by the inhibition of several intracellular pathways, including kinases and small G proteins [30, 40, 41]. Statins inhibit posttranslational modifications of GTPases such as RhoA and Rac1 through the inhibition of isoprenoid intermediates of the cholesterol pathway, such as farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) [40]. RhoA function is regulated through the activation of the Rho-kinase (ROCK) pathway, which is also inhibited by statins and can be activated by arachidonic acid (AA), a polyunsaturated omega-6 fatty acid[42, 43], but not by other types of fatty acids.

The effect of statins on the expression of fibulin family members has not yet been examined. Therefore, the aim of our study was to evaluate whether simvastatin could modify the expression of 4 ECM fibulin family (fibulin-1, -2, -4, and -5) in human coronary artery smooth muscle cells (SMCs). Our results indicate that simvastatin increases the expression of fibulin-2 in human coronary artery SMCs through a RhoA/ROCK-dependent mechanism.

Methods
Reagents
Medium 231, smooth muscle growth supplement (SMGS) and gentamicin/amphotericin B solution were purchased from Cascade Biologics (Madrid, Spain). Simvastatin sodium salt was purchased from Calbiochem (Darmstadt, Germany). GGPP, FPP and fatty acids [palmitic (PA), oleic (OA), linoleic (LA), AA, eicosapentaenoic (EPA) and docosahexaenoic (DHA)]
were purchased from Sigma-Aldrich (Madrid, Spain). Y-27632 dihydrochloride and NSC 23766 were purchased from Tocris Bioscience (Bristol, United Kingdom). Dimethyl sulfoxide (DMSO) was purchased from Merck (Darmstadt, Germany).

Human coronary artery smooth muscle cell culture

Three different lots of human coronary artery SMCs were purchased from Cascade Biologics (4C0915, 4C1284, and 886619). The donor for lot number 4C0915 was a 19-year-old male; for lot number 4C1284, a 21-year-old male; and for lot number 886619, a 36-year-old woman. The cells were cultured in medium 231 (HEPES + bicarbonate) supplemented with SMGS (fetal bovine serum (4.9% v/v), human fibroblast grow factor (2 ng/ml), human epidermal grow factor (0.5 ng/ml), heparin (5 ng/ml), insulin (5 μg/ml) and bovine serum albumin (0.2 μg/ml)) and gentamicin/amphotericin B solution at a density of 2500 cells/cm² according to the manufacturer's protocol. Cells were grown at 37°C under a humidified atmosphere and 5% CO₂. The experiments were performed when cells had grown to 80–90% confluence. The experiments were reproduced using the three different lots of cells. The lot of cells used in each experiment is stated in the Figure Legend of each Figure.

Effect of simvastatin on fibulins

Human coronary artery SMCs were incubated with a wide range of concentrations of simvastatin (0.05, 0.1, 0.5, 1 μM) for 6 or 24 hours. Depending on the objective of the experiments, cells were used for either total RNA or protein extraction. Cells incubated with vehicle alone (untreated cells) were designated as control.

Effect of mevalonate, GGPP, FPP, NCS 23766 and Y-27632 on fibulin-2 mRNA expression

Human coronary artery SMCs were pre-incubated for 2 hours with mevalonate (100 and 200 μM), GGPP (15 μM), and FPP (15 μM), and with the Rho kinase inhibitor Y-27632 (10, 15, 20 μM), and the Rac-1 inhibitor (another member of Rho family) NSC23766 (100 μM) for 24 hours. After incubation, cells were used for total RNA isolation. Cells incubated with vehicle alone (untreated cells) were designated as control. In some cases the culture media was kept at -80°C for fibulin 2 protein determination.

Preparation of Fatty acid (FA) sodium salt and FA-BSA complex

Preparation was made with some modifications according to the method of Wu et al.[44] Ten milligrams of each FA were mixed with 0.5 ml EtOH and 5 M NaOH in a 1:1 ratio volume of FA to NaOH. The mixture was dried under nitrogen gas until the FA sodium salt formed. The salt was then dissolved in 2 ml sterile water (stock solutions of FA). To avoid FA oxidation, 1 μM BHT was added to the FA stock solutions. Stock solutions of FA complexed to BSA were made by mixing FA and 5 mM BSA in a 3:1 ratio of FA to BSA. The FA-BSA solution was sterile-filtered and used fresh.

Effect of FA-BSA on fibulin-2 mRNA expression

Human coronary artery SMCs were incubated with FA-BSA at 25, 50 or 100 μM for 24 h. The fatty acids used were PA, OA, LA, AA, EPA and DHA. Cells were used for total RNA extraction. Cells incubated with vehicle alone (untreated cells) were designated as control.
Cytotoxicity

The potential cytotoxic effect of all compounds on human coronary artery SMCs was assessed by lactate dehydrogenase (LDH) release in the culture medium using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega; Madrid, Spain) following the manufacturer’s instructions and by observing cellular morphology (Olympus IX71; Barcelona, Spain). We did not observe any cytotoxic effect of the compounds used at the concentrations and times described.

RNA isolation

Cells were lysed in lysis buffer, and total RNA was isolated from the cells using the ABI PRISM 6100 Nucleic Acid PrepStation (Life Technologies; Madrid, Spain) following the manufacturer’s instructions. The absorbance at 260 nm was used to measure the RNA concentration, and the 260/280 nm absorbance ratio was used to analyze RNA quality.

Quantitative real-time polymerase chain reaction

A total of 0.5 μg RNA was reverse transcribed to cDNA using Random Hexamers and SuperScript II (Life Technologies) following the manufacturer’s protocol. Taqman primers and probes for fibulin-1, -2, -4 and -5, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and 18s were obtained from validated and pre-designed Gene Expression Assays (Life Technologies) and were used in real-time polymerase chain reaction (rtPCR) amplifications. mRNA expression for each gene and sample was calculated using the recommended $2^{-\Delta\Delta C_{t}}$ method. The control group (untreated cells) was defined as the calibrator in this experiment. GAPDH and 18s were used as housekeeping genes to normalize the results of the gene of interest.

Fibulin protein extraction and quantification

The culture plates were placed on ice and the medium was removed and kept at -80°C. Next, the plates were washed with phosphate buffered saline (PBS). Then, 800 µl of PBS was added, and the cells were scraped from the surface of the culture plates with a cell filter and centrifuged at 1500 rpm for five minutes at 4°C. The supernatant was discarded. A total of 100 µl hypotonic buffer was added, and the samples were passed through a syringe with a 26½ G needle. Next, the samples were centrifuged at 16,000 x g for 10 minutes at 4°C. The supernatant, now containing cytoplasmic extracts, was stored at -80°C. For protein quantification, a Qubit Fluorometer (Life Technologies) was used.

Secreted fibulin-2 in the cell medium was determined by commercial ELISA kits (Uscn Life Science, Inc.), according to the instructions.

Western blotting

Human coronary artery SMCs were cultured as previously described and incubated with simvastatin at concentrations of 0.05–1 μM for 6 or 24 hours. For fibulin-1 and fibulin-2, cell extracts were denatured in 20X Tris-Acetate SDS Running Buffer, separated on Novex 3–8% Tris-Acetate gels (Life Technologies) and transferred to nitrocellulose membranes (0.45 μM). This procedure was also followed for fibulin-2 determination in the cell medium prior to concentration of the samples with Amicon 10K centrifugal filters (Millipore). For fibulin-5, cell extracts were denatured in 20X MOPS SDS Running Buffer, separated on Novex 10% Bis-Tris gels (Life Technologies) and transferred to nitrocellulose membranes (0.22 μM). The membranes were blocked in 1X Tris-buffered saline (TBS), 0.1% Tween and 4% ECL advance (Western blotting detection kit (GE Healthcare; Barcelona, Spain)) for 1 hour, washed in 1X...
TBS and incubated with fibulin-1 and -5, actin (1:500) (Santa Cruz Biotechnology; Heidelberg, Germany) or fibulin-2 (1:500) (Novus biologics; Cambridge, United Kingdom) antibodies overnight at 4°C with continuous shaking. After further washing in 10% 1x TBS, 1% SDS and 0.5% Nonidet P-40, the blots were incubated for 30 minutes with secondary anti-goat P-0049 antibodies (1:10,000) (DACO; Barcelona, Spain) for fibulin-1, fibulin-5, and actin and with secondary anti-rabbit P-0048 antibodies (1:10,000) (DACO) for fibulin-2. Bands were visualized using ECL reagents (Life Technologies) with Versadoc (Bio Rad; Barcelona, Spain), normalized to actin expression and quantified with Quantity One Analysis Software version 4.6.2.

Statistical analysis

All of the results are expressed as the Mean ± Standard Error of the Mean (SEM). The number of independent experiments conducted for each result is stated in the Figure Legends. Statistical analyses were performed using one-way analysis of variance (ANOVA), followed by Dunett post-test correction for multiple comparisons. Differences were considered significant at \( p < 0.05 \). Statistical analyses were performed using GraphPad Prism software (San Diego, California, USA) version 5.01.

Results

Effect of simvastatin on fibulin expression

Six hours after simvastatin treatment, fibulin-1, -2, -4, and -5 mRNA levels were unchanged (S1 Fig). However, after 24 hours of treatment, simvastatin produced a significant increase in fibulin-2 mRNA levels in human coronary artery SMCs compared to controls (Fig 1). The lowest simvastatin concentration showing a significant effect was 0.1 \( \mu \)M with a 1.7-fold increase in fibulin 2 mRNA levels. The maximum effect of simvastatin was at 1 \( \mu \)M with a 2.9-fold increase. In addition to increasing fibulin-2 mRNA expression, simvastatin treatment also increased fibulin-2 protein expression. We quantified western blot band intensity and normalized them to actin expression and found a significant increase with a maximum effect also at a concentration of 1 \( \mu \)M with a 2.1-fold increase (Fig 1). In contrast, mRNA and protein levels of fibulin-1, -4, and -5 did not change, after 24 hours of simvastatin treatment (S1 and S2 Tables).

Mevalonate reverses simvastatin-induced fibulin 2 expression

By inhibiting HMG-CoA reductase, statins cause a depletion of mevalonate in the cells. To determine whether this depletion was involved in simvastatin increase of fibulin 2 expression, we incubated human coronary artery SMCs with simvastatin alone (1 \( \mu \)M) or in combination with mevalonate. We found that pre-incubating the cells for 2 hours with increasing concentrations of mevalonate (100, 200 \( \mu \)M), completely and significantly reversed the simvastatin-dependent induction of fibulin 2 mRNA and protein (Fig 2), confirming the specificity of simvastatin’s effect. Mevalonate alone did not affect fibulin 2 mRNA or protein expression. Furthermore, we showed that mevalonate alone or in combination with simvastatin did not affect fibulin -1, -4, or -5 gene expression (S2 Fig).

Effect of simvastatin on secreted fibulin-2 expression

To determine whether the intracellular effects described above for fibulin-2 were valid for secreted fibulin-2, the culture media of those experiments were analyzed by ELISA and western blotting. We found that simvastatin (1 \( \mu \)M) significantly increased secreted fibulin-2 concentration (Fig 3) after 24 h of incubation and that pre-incubating the cells with mevalonate (200 \( \mu \)M), completely and significantly reversed the simvastatin-dependent induction of
Simvastatin Increases Fibulin-2 Expression

A

![Graph showing Fibulin 2 mRNA expression](Image)

- Control
- 0.05
- 0.1
- 0.5
- 1

Fibulin 2 mRNA (2^(-ΔΔCt))

- p<0.05
- p<0.05
- p<0.05

B

![Fibulin 2 and Actin Western Blot](Image)

- Fibulin 2 195 KDa
- Actin 43 KDa

- p<0.05
- p<0.05

Fibulin 2/Actin (fold increase)

- Control
- 0.1
- 0.5
- 1
secreted fibulin protein (Fig 3). These results confirm the specificity of the effect of simvastatin and provide evidence of the secretion of fibulin-2 by these cells. Mevalonate alone did not affect soluble fibulin 2 expression.

**Downstream isoprenoids are involved in simvastatin effect**

Mevalonate is a precursor of isoprenoid compounds such as FPP and GGPP in the cholesterol biosynthetic pathway. To evaluate which downstream isoprenoid was involved in fibulin 2 mRNA expression, we incubated human coronary artery SMCs with simvastatin alone or in combination with one of the isoprenoids. We found that GGPP (15 μM) but not FPP (15 μM) markedly reversed simvastatin-induced fibulin 2 mRNA expression, whereas the respective isoprenoids alone had no effect (Fig 4A). These results were specific for fibulin 2 because no change in the mRNA levels of fibulin-1, -4, or -5 was observed after incubation of cells with isoprenoids alone or in combination with simvastatin (S3 Fig).

**ROCK inhibitor Y-27632 upregulates fibulin 2 expression**

Because ROCK is one of the major downstream targets of RhoA, we next evaluated in human coronary artery SMCs the involvement of the RhoA/ROCK pathway on simvastatin-induced fibulin-2 expression. As shown in Fig 4B, treatment of cells with the selective ROCK inhibitor Y-27632 significantly increased fibulin-2 mRNA levels. We found that 24 h treatment with Y-27632 at 10, 15 and 20 μM significantly increased fibulin-2 mRNA expression by 1.5, 2.6, and 2.3-fold, respectively. In contrast, treatment with the selective Rac-1 inhibitor NSC23766 had no effect on fibulin-2 mRNA levels (Fig 4B). Again, this effect was specific for fibulin-2 because incubation of cells with different concentrations of the ROCK inhibitor did not affect the mRNA levels of any of the other fibulins tested (fibulin-1, -4, and -5) (S4 Fig).

**Arachidonic acid, but not other FAs, decreases fibulin-2 gene expression**

It is well known that AA, but not PA, OA, LA, EPA or DHA, activates the RhoA/ROCK pathway. Therefore, we tested whether RhoA/ROCK pathway activation with increasing AA concentrations affected fibulin 2 expression. As shown in Fig 5, AA produced a significant decrease in fibulin-2 mRNA levels compared to controls. At 50 and 100 μM, we observed a 45% and 42% decrease, respectively. However, PA, OA, LA, EPA and DHA had no significant effect on fibulin 2 mRNA expression at any of the concentrations used (S5 Fig).

**Discussion**

The main objective of the current study was to evaluate whether simvastatin treatment could affect the expression of 4 fibulin family members (fibulin-1, -2, -4, and -5) and the mechanisms involved. We have shown that 24 hours of simvastatin treatment of human coronary artery SMCs upregulates intracellular and secreted fibulin-2 expression at both the mRNA and protein levels. This effect is specific to fibulin-2, as neither fibulin-1, -4 nor -5 were affected by simvastatin treatment. Moreover, we have shown that the mechanism involved is a depletion in...
Fig 2. A: Effect of mevalonate on simvastatin-induced fibulin-2 mRNA levels in human coronary artery SMCs. Cells were preincubated for 2 hours with mevalonate (100, 200 μM) and treated with simvastatin for 24 hours. B: Effect of mevalonate on simvastatin-induced fibulin-2 protein levels in human coronary artery SMCs. Cells were preincubated for 2 hours with mevalonate (200 μM) and treated with simvastatin for 24 hours. Blot bands were normalized to actin and quantified with Quantity One Analysis Software version 4.6.2. A representative Western blot is shown. The results are shown as the mean with
the cells of mevalonate and GGPP. Simvastatin by inhibiting the rate-limiting enzyme in the
cholesterol synthesis pathway HMG-CoA reductase, decrease levels of these compounds which
are intermediates of the pathway. Because GGPP is also responsible for the posttranslational
activation of the small GTPase RhoA, the simvastatin-induced depletion of GGPP is linked to
an inhibition of RhoA and its effector ROCK. In addition, we observed that the inhibition of
ROCK was specific, as treatment with a ROCK inhibitor (Y-27632) increased fibulin-2 expres-
sion whereas treatment with a Rac inhibitor (NCS23766) did not. Furthermore, neither meva-
lonate nor GGPP, FPP, Y-27633, or NSC23766 affect the expression of fibulins -1, -4 or -5. We
also found that the induction of RhoA/ROCK pathway with AA decreased fibulin 2 expression.
To our knowledge, the simvastatin-induced increase in fibulin-2 expression reported here is a novel non-lipid related effect of simvastatin. Because simvastatin
is a lipophilic statin, extrapolation of our results to hydrophilic statins would be just specula-
tion. Therefore, new experiments should be performed with this type of statins to confirm
these results.

Statins primarily protect against coronary disease by reducing lipid levels. However, pleio-
tropic effects of statins can further protect patients on statin therapy. These effects are well
categorized and include improvement in endothelial dysfunction, increased nitric oxide bio-
availability, antioxidant properties, reduction of blood thrombogenicity, and inhibition of pro-
inflammatory responses[29–31].

Fibulin 2 has important features in connection with atherosclerosis. It is an important com-
ponent of the vascular ECM and can influence the organization and structure of the vascular
wall[45–48] by binding to matrix components such as proteoglycans, fibronectin, fibrillin, and
laminins [17, 45, 46, 49–51]. Additionally, fibulin 2 can bind to tropoelastin and to fibrillin-1,
suggesting that it may act as an anchor for elastin to microfibrils[18, 48, 52]. Moreover, it has
been shown in murine models that fibulin-2 is expressed in SMC-rich regions of atheroscle-
rotic lesions, where it colocalizes with versican and hyaluronan[28]. Moreover, it has been
shown that thinning of the plaque fibrous cap and the presence of immature intraplaque
neovessels are key events in the transformation of atherosclerotic plaques to a vulnerable phe-
notype, thus contributing to the onset of complications[53]. In this regard, an important pleio-
tropic effect of statins is the improvement in the characteristics that stabilizes atherosclerotic
plaques[37, 39]. For instance, 12-month treatment of patients with atorvastatin has resulted in
significant increases in the fibrotic content of the plaque [36]. Immunohistochemistry studies
of human carotid plaques have shown that patients on pravastatin have plaques with a signifi-
cant higher collagen content [35]. Moreover, 9-month statin treatment after acute myocardial
infarction significantly increased the fibrous-cap thickness in patients with hyperlipidemia[38].
But fibulin-2 not only is a scaffold protein, there is also evidence that it has a regulatory func-
tion because it can modify SMC migration[28, 51]. Moreover, it has been proposed that
changes in fibulin-2 structure or levels may partially control systolic blood pressure[54]. Over-
all, the role of fibulin-2 in the atherosclerotic process needs to be clarified with more studies.

We describe a mechanism that has been widely reported as a mode of action of statins.
One example related to the stabilization effect of statins is that statins inhibit MMP-2 and
MMP-9 secretion through the suppression of RhoA activation and Rab prenylation, respecti-
vely[55, 56]. Statins inhibit the isoprenylation of small G-proteins by inhibiting the synthesis
Fig 3. Effect of simvastatin and mevalonate in secreted fibulin 2 expression in culture medium from human coronary artery SMCs. Cells were preincubated for 2 hours with mevalonate (200 μM) and treated with simvastatin for 24 hours. Blot bands were normalized to actin and quantified with Quantity One Analysis Software version 4.6.2. A representative Western blot is shown. The results are shown as the mean with the standard error of the mean (SEM) for four independent experiments in 3A (1 with cell lot number 4C1284 and 3 with cell lot number 886619) and three independent experiments in 2B with cell lot number 886619. Comparisons were performed using ANOVA followed by Dunett post-test correction.

doi:10.1371/journal.pone.0133875.g003
Fig 4. Effect of GGPP and FPP (A) and the ROCK inhibitor Y-27632 and Rac inhibitor NCS23766 (B) on simvastatin-induced fibulin-2 mRNA levels in human coronary artery SMCs. Cells were incubated with simvastatin and isoprenoids or with the inhibitors for 24 hours. The results are shown as the mean with the standard error of the mean (SEM) for twelve independent experiments in both A and B (2 with cell lot number 4C0915, 4 with cell lot number 4C1284, and 6 with cell lot number 886619). Comparisons were performed using ANOVA followed by Dunnett post-test correction. FPP: farnesyl pyrophosphate, GGPP: geranylgeranyl pyrophosphate.

doi:10.1371/journal.pone.0133875.g004
of important isoprenoids, which prevents the attachment of the small G-proteins to the cell membrane, thereby inhibiting their ability to transduce signals through MAPK pathways.

In conclusion, the simvastatin-induced upregulation of fibulin-2 expression may affect the composition and structure of the ECM. Whether this effect has a beneficial impact on atherosclerosis plaque characteristics needs further investigation.

Supporting Information

S1 Fig. Effect of simvastatin on fibulin-1, -2, -4 and -5 mRNA levels in human coronary artery SMCs. Cells were treated with simvastatin for 6 hours. The results are shown as the mean with the standard error of the mean for three independent experiments (2 with cell lot number 4C0915 and 1 with cell lot number 4C1284). Comparisons were performed using ANOVA followed by Dunnett post-test correction. (DOCX)

S2 Fig. Effect of mevalonate and simvastatin on fibulin-1, -4, and -5 mRNA levels in human coronary artery SMCs. Cells were pre incubated for 2 hours with mevalonate (100 μM) and treated with simvastatin (1μM) for 24 hours. The results are shown as the mean with the standard deviation for at least three independent experiments. Comparisons were performed using ANOVA followed by Dunett post-test correction. (DOCX)

S3 Fig. Effect of FPP, GGPP, and simvastatin on fibulin-1, -4, and -5 mRNA levels in human coronary artery SMCs. Cells were incubated with simvastatin (1μM) and isoprenoids (15μM) for 24 hours. The results are shown as the mean with the standard deviation for at least three independent experiments. Comparisons were performed using ANOVA followed by Dunnett post-test correction. FPP: farnesyl pyrophosphate, GGPP: geranylgeranyl pyrophosphate, Simv: simvastatin. (DOCX)

S4 Fig. Effect of the ROCK inhibitor Y-27632 and Rac inhibitor NCS23766 on fibulin-1, -4, and -5 mRNA levels in human coronary artery SMCs. Cells were incubated with the
inhibitors for 24 hours. The results are shown as the mean with the standard deviation for at least three independent experiments. Comparisons were performed using ANOVA followed by Dunnett post-test correction.

(S5 Fig) Effect of fatty acids on fibulin-2 mRNA levels in human coronary artery SMCs. Cells were treated with different concentrations of fatty acids for 24 hours. The results are shown as the mean with the standard deviation for three independent experiments. Comparisons were performed using ANOVA followed by Dunnett post-test correction. PA: Palmitic acid, OA: oleic acid, LA: linoleic acid, EPA: eicosapentaenoic acid, DHA: docosahexaenoic acid.

(S1 Table) Effect of simvastatin on fibulin-1, -4, and -5 mRNA levels in human coronary artery SMCs. Cells were treated with different concentrations simvastatin for 24 hours. The results are shown as the mean with standard deviation for three independent experiments. Comparisons were performed using ANOVA followed by Dunnett post-test correction.

(S2 Table) Effect of simvastatin on fibulin-1 and -5 protein levels in human coronary artery SMCs. Cells were treated with different concentrations simvastatin for 24 hours. The results are shown as the mean with standard deviation for three independent experiments. Comparisons were performed using ANOVA followed by Dunnett post-test correction.

Author Contributions
Conceived and designed the experiments: LM JCV. Performed the experiments: NS RR JCV. Analyzed the data: NS JCV. Contributed reagents/materials/analysis tools: NS RR. Wrote the paper: JCV LM.

References
1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Executive summary: heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014; 129(3):399–410. doi:10.1161/01.cir.0000442015.53336.12 PMID: 24444611.
2. Mackay J, Mensah G, editors. WHO: The Atlas of Heart Disease and Stroke2004; Brighton BN1 1EJ.
3. Green J, Yurdagul A Jr., McInnis MC, Albert P, Orr AW. Flow patterns regulate hyperglycemia-induced subendothelial matrix remodeling during early atherogenesis. Atherosclerosis. 2014; 232(2):277–84. doi: 10.1016/j.atherosclerosis.2013.11.052 PMID: 24468139; PubMed Central PMCID: PMC3905249.
4. Schaar JA, Muller JE, Falk E, Virmani R, Fuster V, Serruys PW, et al. Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur Heart J. 2004; 25(12):1077–82. doi: 10.1016/j.ehj.2004.01.002 PMID: 15191780.
5. ten Kate GL, Sijbrands EJ, Staub D, Coll B, ten Cate FJ, Feinstein SB, et al. Noninvasive imaging of the vulnerable atherosclerotic plaque. Current problems in cardiology. 2010; 35(11):556–91. doi: 10.1016/j.cpcardiol.2010.09.002 PMID: 20974314.
6. Herman MP, Sukhova GK, Libby P, Gerdes N, Tang N, Horton DB, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation. 2001; 104(16):1899–904. PMID: 11602491.
7. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation. 1995; 92(6):1565–9. PMID: 7664441.
8. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A prospective natural-history study of coronary atherosclerosis. The New England journal of medicine. 2011; 364(3):226–35. doi: 10.1056/NEJMoa1002358 PMID: 21247313.

9. Davies MJ. The pathophysiology of acute coronary syndromes. Heart. 2000; 83(3):361–6. PMID: 10677422; PubMed Central PMCID: PMC1729334.

10. Falk E. Pathogenesis of atherosclerosis. Journal of the American College of Cardiology. 2006; 47(8 Suppl):C7–12. doi: 10.1016/j.jacc.2005.09.068 PMID: 16631513.

11. Doyle B, Caplice N. Plaque neovascularization and antiangiogenic therapy for atherosclerosis. Journal of the American College of Cardiology. 2007; 49(21):2073–80. doi: 10.1016/j.jacc.2007.01.089 PMID: 17531655.

12. Jeziorska M, Woolley DE. Local neovascularization and cellular composition within vulnerable regions of atherosclerotic plaques of human carotid arteries. The Journal of pathology. 1999; 188(2):189–96. doi: 10.1002/(SICI)1096-9896(199906)188:2<189::AID-PATH336>3.0.CO;2-N PMID: 10398163.

13. Moreno PR, Purushothaman KR, Fuster V, Echeverri D, Truszczynska H, Sharma SK, et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation. 2004; 110(14):2032–8. doi: 10.1161/01.CIR.0000143233.87854.23 PMID: 15451780.

14. Moreno PR, Purushothaman KR, Sirol M, Levy AP, Fuster V. Neovascularization in human atherosclerosis. Circulation. 2006; 113(18):2245–52. doi: 10.1161/CIRCULATIONAHA.105.578955 PMID: 16684874.

15. Argraves WS, Greene LM, Cooley MA, Gallagher WM. Fibulins: physiological and disease perspectives. EMBO reports. 2003; 4(12):1127–31. doi: 10.1038/sj.embor.7400033 PMID: 14647206; PubMed Central PMCID: PMC1326425.

16. Chu ML, Tsuda T. Fibulins in development and heritable disease. Birth defects research Part C, Embryo today: reviews. 2004; 72(1):25–36. doi: 10.1002/bdrc.20003 PMID: 15054902.

17. Longmate WM, Monichan R, Chu ML, Tsuda T, Mahoney MG, DiPersio CM. Reduced Fibulin-2 Contributes to Loss of Basement Membrane Integrity and Skin Blistering in Mice Lacking Integrin alpha3-beta1 in the Epidermis. The Journal of investigative dermatology. 2014; 134(6):1609–17. doi: 10.1038/jid.2014.10 PMID: 24390135; PubMed Central PMCID: PMC4020984.

18. Yanagisawa H, Davis EC. Unraveling the molecular mechanism of elastic fiber assembly: The roles of short fibulins. The international journal of biochemistry & cell biology. 2010; 42(7):1084–93. doi: 10.1016/j.biocel.2010.03.009 PMID: 20236620; PubMed Central PMCID: PMC2880191.

19. Noda K, Dabovic B, Takagi K, Inoue T, Horiguchi M, Hirai M, et al. Latent TGF-beta binding protein 4 promotes elastic fiber assembly by interacting with fibulin-5. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(8):2852–6. doi: 10.1073/pnas.1215779110 PMID: 23832201; PubMed Central PMCID: PMC3581912.

20. Sideek MA, Menz C, Parsi MK, Gibson MA. LTBP-2 competes with tropoelastin for binding to fibulin-5 and heparin, and is a negative modulator of elastinogenesis. Matrix biology: journal of the International Society for Matrix Biology. 2014; 34:114–21. doi: 10.1016/j.matbio.2013.10.007 PMID: 24148803.

21. Sicot FX, Tsuda T, Markova D, Klement JF, Arita M, Zhang RZ, et al. Fibulin-2 is dispensable for mouse development and elastic fiber formation. Molecular and cellular biology. 2008; 28(3):1061–7. doi: 10.1128/MCB.01876-07 PMID: 18070922; PubMed Central PMCID: PMC2223402.

22. Laugesen E, Hoyem P, Christiansen JS, Knudsen ST, Hansen KW, Argraves WS, et al. Plasma levels of the arterial wall protein fibulin-1 are associated with carotid-femoral pulse wave velocity: a cross-sectional study. Cardiovascular diabetology. 2013; 12(1):107. doi: 10.1186/1475-2840-12-107 PMID: 23866070; PubMed Central PMCID: PMC3722025.

23. Schole A, Bladbjerg EM, Sidelmann JJ, Diederichsen AC, Mickley H, Nybo M, et al. Plasma concentrations of extracellular matrix protein fibulin-1 are related to cardiovascular risk markers in chronic kidney disease and diabetes. Cardiovascular diabetology. 2013; 12:6. doi: 10.1186/1475-2840-12-6 PMID: 23294625; PubMed Central PMCID: PMC3570481.

24. Sawyer SL, Dicke F, Kirton A, Rajapakse T, Rebeyka IM, McInnes B, et al. Longer term survival of a child with autosomal recessive cutis laxa due to a mutation in FBLN4. American journal of medical genetics Part A. 2013; 161A(5):1148–53. doi: 10.1002/ajmg.a.35827 PMID: 23532871.

25. Pass HI, Levin SM, Harbut ML, Melamed J, Chiriboga L, Donington J, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. The New England journal of medicine. 2012; 367(15):1417–27. doi: 10.1056/NEJMoa1115080 PMID: 23050625; PubMed Central PMCID: PMC3767121.

26. Hu B, Nandhu MS, Sim H, Agudelo-Garcia PA, Saldivar JC, Dolan CE, et al. Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of Notch signaling. Cancer research. 2012;
Simvastatin Increases Fibulin-2 Expression

27. Stone EM, Braun TA, Russell SR, Kuehn MH, Lotery AJ, Moore PA, et al. Missense variations in the fibulin 5 gene and age-related macular degeneration. The New England journal of medicine. 2004; 351(4):346–53. doi: 10.1056/NEJMoa040833 PMID: 15269314.

28. Strom A, Olin Al, Aspberg A, Hultgardh-Nilsson A. Fibulin-2 is present in murine vascular lesions and is important for smooth muscle cell migration. Cardiovascular research. 2006; 69(3):755–63. doi: 10.1016/j.cardiores.2005.12.001 PMID: 16409997.

29. Babelova A, Sedding DG, Brandes RP. Anti-atherosclerotic mechanisms of statin therapy. Current opinion in pharmacology. 2013; 13(2):260–4. doi: 10.1016/j.coph.2013.01.004 PMID: 23402735.

30. Birnbaum Y, Ye Y. Pleiotropic effects of statins: the role of eicosanoid production. Current atherosclerosis reports. 2012; 14(2):135–9. doi: 10.1007/s11883-012-0232-5 PMID: 22286195.

31. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends in molecular medicine. 2008; 14(1):37–44. doi: 10.1016/j.jmolmed.2007.11.004 PMID: 18068482; PubMed Central PMCID: PMC2621332.

32. Libby P, Akawa M. Mechanisms of plaque stabilization with statins. The American journal of cardiology. 2003; 91(4A):48–88. PMID: 12615292.

33. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. The New England journal of medicine. 2013; 368(21):2004–13. doi: 10.1056/NEJMra1216063 PMID: 23697515.

34. Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation. 2001; 103(7):993–9. PMID: 11181475.

35. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA: the journal of the American Medical Association. 2004; 291(9):1071–80. doi: 10.1001/jama.291.9.1071 PMID: 14996776.

36. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001; 103(7):926–33. PMID: 11181465.

37. Nakamura T, Obata JE, Kitta Y, Takano H, Kobayashi T, Fujioka D, et al. Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome. Journal of cardiovascular pharmacology. 2008; 51(4):365–71. doi: 10.1097/FJC.0b013e318165dcad PMID: 18427279.

38. Takarada S, Imanishi T, Kubo T, Tanimoto T, Kitabata H, Nakamura N, et al. Effect of statin therapy on coronary fibrous-cap thickness in patients with acute coronary syndrome: assessment by optical coherence tomography study. Atherosclerosis. 2009; 202(2):491–7. doi: 10.1016/j.atherosclerosis.2008.05.014 PMID: 18572175.

39. Hattori K, Ozaki Y, Ismail TF, Okumura M, Naruse H, Kan S, et al. Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS. JACC Cardiovascular imaging. 2012; 5(2):169–77. doi: 10.1016/j.jcmg.2011.11.012 PMID: 23408233.

40. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004; 109(23 Suppl 1): III39–43. doi: 10.1161/01.CIR.0000131517.20177.5a PMID: 15198965.

41. Ruperez M, Rodrigues-Diez R, Blanco-Colio LM, Sanchez-Lopez E, Esteban V, et al. HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: role of RhoA/ROCK and MAPK pathways. Hypertension. 2007; 50(2):377–83. doi: 10.1161/HYPERTENSIONAHA.107.091264 PMID: 17592071.

42. Garcia MC, Williams J, Johnson K, Olden K, Roberts JD. Arachidonic acid stimulates formation of a novel complex containing nucleolin and RhoA. FEBS letters. 2011; 585(4):618–22. doi: 10.1016/j.febslet.2011.01.035 PMID: 21281639; PubMed Central PMCID: PMC3098762.

43. Brown M, Roulosson JA, Hart CA, Tawadros T, Clarke NW. Arachidonic acid induction of Rho-mediated transendothelial migration in prostate cancer. British journal of cancer. 2014; 110(8):2099–108. doi: 10.1038/bjc.2014.99 PMID: 24595005; PubMed Central PMCID: PMC3992515.

44. Wu X, Shang A, Jiang H, Ginsberg HN. Demonstration of biphasic effects of docosahexaenoic acid on apolipoprotein B secretion in HepG2 cells. Atherosclerosis, thrombosis, and vascular biology. 1997; 11(11):3347–55. PMID: 9409332.

45. Sasaki T, Goering W, Pan TC, Chu ML, Timpl R. Binding of mouse and human fibulin-2 to extracellular matrix ligands. Journal of molecular biology. 1995; 254(5):892–9. doi: 10.1006/jmbi.1995.0664 PMID: 7500359.
46. Olin AL, Morgelin M, Sasaki T, Timpl R, Heinegard D, Aspberg A. The proteoglycans aggrecan and Versican form networks with fibulin-2 through their lectin domain binding. The Journal of biological chemistry. 2001; 276(2):1253–61. doi: 10.1074/jbc.M006783200 PMID: 11038354.

47. Utani A, Nomizu M, Yamada Y. Fibulin-2 binds to the short arms of laminin-5 and laminin-1 via conserved amino acid sequences. The Journal of biological chemistry. 1997; 272(5):2814–20. PMID: 9006922.

48. Reinhardt DP, Sasaki T, Dzamba BJ, Keene DR, Chu ML, Gohring W, et al. Fibrillin-1 and fibulin-2 interact and are colocalized in some tissues. The Journal of biological chemistry. 1996; 271(32):19489–96. PMID: 8702639.

49. Gu YC, Nilsson K, Eng H, Ekblom M. Association of extracellular matrix proteins fibulin-1 and fibulin-2 with fibronectin in bone marrow stroma. British journal of haematology. 2000; 109(2):305–13. PMID: 10848816.

50. Sasaki T, Wiedemann H, Matzner M, Chu ML, Timpl R. Expression of fibulin-2 by fibroblasts and deposition with fibronectin into a fibrillar matrix. Journal of cell science. 1996; 109(Pt 12):2895–904. PMID: 9013337.

51. Yi CH, Smith DJ, West WW, Hollingsworth MA. Loss of fibulin-2 expression is associated with breast cancer progression. The American journal of pathology. 2007; 170(5):1535–45. doi: 10.2353/ajpath.2007.060478 PMID: 17456760; PubMed Central PMCID: PMC1854949.

52. Papke CL, Yanagisawa H. Fibulin-4 and fibulin-5 in elastogenesis and beyond: Insights from mouse and human studies. Matrix biology: journal of the International Society for Matrix Biology. 2014. doi: 10.1016/j.matbio.2014.02.004 PMID: 24613575.

53. Hinz B, Phan SH, Than Nickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. The American journal of pathology. 2007; 170(6):1807–16. doi: 10.2353/ajpath.2007.070712 PMID: 17525249; PubMed Central PMCID: PMC1899462.

54. Vallve JC, Serra N, Zalba G, Fortuno A, Belouqui O, Ferre R, et al. Two variants in the fibulin2 gene are associated with lower systolic blood pressure and decreased risk of hypertension. PloS one. 2012; 7(8):e43051. doi: 10.1371/journal.pone.0043051 PMID: 22912785; PubMed Central PMCID: PMC3418224.

55. Li M, Li Z, Sun X. Statins suppress MMP2 secretion via inactivation of RhoA/ROCK pathway in pulmonary vascular smooth muscles cells. European journal of pharmacology. 2008; 591(1–3):219–23. doi: 10.1016/j.ejphar.2008.06.082 PMID: 18619957.

56. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arteriosclerosis, thrombosis, and vascular biology. 1998; 18(11):1671–8. PMID: 9812903.